Literature DB >> 26506247

The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.

John M Louis1, James L Baber1, G Marius Clore1.   

Abstract

The conformational transition of the core domain of HIV-1 gp41 from a prehairpin intermediate to a six-helix bundle is responsible for virus-cell fusion. Several inhibitors which target the N-heptad repeat helical coiled-coil trimer that is fully accessible in the prehairpin intermediate have been designed. One such inhibitor is the peptide C34 derived from the C-heptad repeat of gp41 that forms the exterior of the six-helix bundle. Here, using a variety of biophysical techniques, including dye tagging, size-exclusion chromatography combined with multiangle light scattering, double electron-electron resonance EPR spectroscopy, and circular dichroism, we investigate the binding of C34 to two six-helix bundle mimetics comprising N- and C-heptad repeats either without (core(SP)) or with (core(S)) a short spacer connecting the two. In the case of core(SP), C34 directly exchanges with the C-heptad repeat. For core(S), up to two molecules of C34 bind the six-helix bundle via displacement of the C-heptad repeat. These results suggest that fusion inhibitors such as C34 can target a continuum of transitioning conformational states from the prehairpin intermediate to the six-helix bundle prior to the occurrence of irreversible fusion of viral and target cell membranes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26506247      PMCID: PMC5576721          DOI: 10.1021/acs.biochem.5b01021

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  64 in total

1.  Dead-time free measurement of dipole-dipole interactions between electron spins.

Authors:  M Pannier; S Veit; A Godt; G Jeschke; H W Spiess
Journal:  J Magn Reson       Date:  2000-02       Impact factor: 2.229

Review 2.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

3.  Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion.

Authors:  Julien Roche; John M Louis; Alexander Grishaev; Jinfa Ying; Adriaan Bax
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

4.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 5.  Co-receptors for HIV-1 entry.

Authors:  J P Moore; A Trkola; T Dragic
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

6.  A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Authors:  Rachel P J Lai; Miriam Hock; Jens Radzimanowski; Paul Tonks; David Lutje Hulsik; Gregory Effantin; David J Seilly; Hanna Dreja; Alexander Kliche; Ralf Wagner; Susan W Barnett; Nancy Tumba; Lynn Morris; Celia C LaBranche; David C Montefiori; Michael S Seaman; Jonathan L Heeney; Winfried Weissenhorn
Journal:  J Biol Chem       Date:  2014-08-26       Impact factor: 5.157

7.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

8.  Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Authors:  Elena Gustchina; Mi Li; John M Louis; D Eric Anderson; John Lloyd; Christian Frisch; Carole A Bewley; Alla Gustchina; Alexander Wlodawer; G Marius Clore
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

9.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

10.  Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41.

Authors:  Elena Gustchina; Mi Li; Rodolfo Ghirlando; Peter Schuck; John M Louis; Jason Pierson; Prashant Rao; Sriram Subramaniam; Alla Gustchina; G Marius Clore; Alexander Wlodawer
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more
  5 in total

1.  Real-time Exchange of the Lipid-bound Intermediate and Post-fusion States of the HIV-1 gp41 Ectodomain.

Authors:  Sai Chaitanya Chiliveri; John M Louis; Robert B Best; Ad Bax
Journal:  J Mol Biol       Date:  2022-06-11       Impact factor: 6.151

2.  Sulfono-γ-AA modified peptides that inhibit HIV-1 fusion.

Authors:  Olapeju Bolarinwa; Meng Zhang; Erin Mulry; Min Lu; Jianfeng Cai
Journal:  Org Biomol Chem       Date:  2018-10-31       Impact factor: 3.876

3.  Efficient Fusion at Neutral pH by Human Immunodeficiency Virus gp41 Trimers Containing the Fusion Peptide and Transmembrane Domains.

Authors:  S Liang; P U Ratnayake; C Keinath; L Jia; R Wolfe; A Ranaweera; D P Weliky
Journal:  Biochemistry       Date:  2018-02-06       Impact factor: 3.162

4.  Insights into the Conformation of the Membrane Proximal Regions Critical to the Trimerization of the HIV-1 gp41 Ectodomain Bound to Dodecyl Phosphocholine Micelles.

Authors:  John M Louis; James L Baber; Rodolfo Ghirlando; Annie Aniana; Ad Bax; Julien Roche
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

5.  Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.

Authors:  Vinita R Joshi; Ruchi M Newman; Melissa L Pack; Karen A Power; James B Munro; Ken Okawa; Navid Madani; Joseph G Sodroski; Aaron G Schmidt; Todd M Allen
Journal:  PLoS Pathog       Date:  2020-05-11       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.